MSMahmoud Sadeghi

Mahmoud Sadeghi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mahmoud Sadeghi has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Preoperative CD52 Level Predicts Graft Survival following Kidney Transplantation

    by Ali Ramouz, Rajan Nikbakhsh, Elias Khajeh, Mahmoud Sadeghi, Volker Daniel, Paul Schmitzler, Christian Morath, Martin Zeier, Arianeb Mehrabi, Hani Oweira

    Several factors have been reported to affect graft survival following kidney transplantation. CD52 molecules may increase T cell proliferation and activation, which may contribute to acute graft rejection and graft survival. In the current study, we studied the possible value of preoperative CD52 levels in predicting graft survival following renal transplantation. Ninety‐six patients with end‐stage renal disease who had kidney transplantation were included in the study from our prospective cohort. Blood samples were taken one day before surgery, and plasma CD52 levels were measured using ELISA (Cloud‐Clone Corp., Houston, TX, USA). Acute rejection, acute tubular necrosis, delayed graft function, graft loss, BK infection, cytomegalovirus infection, and graft survival were evaluated. The mean age of recipients was 50.08 ± 12.82 years, and 64.6% were male. The incidence of delayed graft function, acute rejection, graft loss (p < 0.01), BK virus infection, and serum creatinine levels were significantly higher in recipients with high preoperative CD52 levels six months after transplantation (p < 0.05). Kaplan–Meier analysis revealed that three‐year graft survival was significantly higher in patients with low preoperative CD52 levels (p < 0.0001). Univariate and multivariate Cox regression analyses showed that serum creatinine levels (hazard ratio [HR] = 1.7, p < 0.05), acute rejection (HR = 2.919, p < 0.05), and preoperative CD52 levels (HR = 3.114, p < 0.05) were independent prognostic factors for graft survival after kidney transplantation. We showed that high preoperative CD52 levels are associated with higher rates of acute rejection, delayed graft function, and BK virus infection and lower rates of graft survival after kidney transplantation.


  • Toll‐like receptors as novel therapeutic targets for herpes simplex virus infection

    by Rana Jahanban‐Esfahlan, Khaled Seidi, Maryam Majidinia, Ansar Karimian, Bahman Yousefi, Seyed Mohammad Nabavi, Akram Astani, Ioana Berindan‐Neagoe, Diana Gulei, Francesca Fallarino, et al.

    Summary: Seropositivity for HSV reaches more than 70% within the world population, and yet no approved vaccine exists. While HSV1 is responsible for keratitis, encephalitis, and labialis, HSV2 carriers have a high susceptibility to other STD infections, such as HIV. Induction of antiviral innate immune responses upon infection depends on a family of pattern recognition receptors called Toll‐like receptors (TLR). TLRs bridge innate and adaptive immunity by sensing virus infection and activating antiviral immune responses. HSV adopts smart tricks to evade innate immunity and can also manipulate TLR signaling to evade the immune system or even confer destructive effects in favor of virus replication. Here, we review mechanisms by which HSV can trick TLR signaling to impair innate immunity. Then, we analyze the role of HSV‐mediated molecular cues, in particular, NF‐κB signaling, in promoting protective versus destructive effects of TLRs. Finally, TLR‐based therapeutic opportunities with the goal of preventing or treating HSV infection will be discussed.


  • Endothelial precursor cell cross‐match using Tie‐2‐enriched spleen cells

    by Volker Daniel, Caner Süsal, Sabine Scherer, Hien Tran, Petra Gombos, Karina Trojan, Mahmoud Sadeghi, Christian Morath, Gerhard Opelz

    Background: Non‐HLA antibodies against human endothelial progenitor cells (EPC) in pre‐transplant recipient serum can have a deleterious influence on the graft. EPC enriched from peripheral blood have been commonly used for EPC cross‐matching. In the present study, we describe cross‐matches using EPC enriched from fresh or frozen‐thawed spleen cell preparations, thereby widening the sample source for deceased‐donor cross‐matching and retrospective studies.Methods: EPC cross‐matches were performed retrospectively using spleen cells and the flow cytometric XM‐ONE cross‐match test kit.Results: Healthy controls (n = 28) showed no IgG antibodies against EPC. When sera of 11 random dialysis patients were studied, 2 patients (18%) exhibited IgG EPC antibodies. When pre‐transplant sera of 20 kidney graft recipients with good long‐term graft outcome (serum creatinine 1.0 ± 0.2 mg/dL measured 2463 ± 324 days post‐transplant) were investigated using frozen‐thawed and then separated Tie‐2‐enriched spleen cells of the original transplant donor, 3 patients (15%) had pre‐transplant IgG EPC antibodies. When pre‐transplant sera of 5 patients with intra‐operative graft loss were studied employing the original donor spleen cells, 4 (80%) patients showed IgG EPC antibodies.Conclusions: Cross‐matches with spleen cell‐derived EPC using the XM‐ONE assay are technically possible. Our very preliminary experience suggests clinical relevance.